Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BCAX, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Ficerafusp Alfa (BCA101) | Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2/3 · NCT06788990 | Recruiting |
Also used in these trials (approved or third-party drugs, not BCAX's own candidates): Pembrolizumab, Nivolumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BCAX holds $497.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $40.9M/quarter from operations, an estimated runway of 36.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 17 · Low
Based upon our current operating plans, we believe that our existing cash, cash equivalents and marketable securities, will be sufficient to fund our operations and capital expenditure requirements into the first half of 2029.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BCAX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. | Institution (13G, 5%+) | 7,279,739 | 11.00% | 2026-02-26 |
| T. Rowe Price Investment Management, Inc | Institution (13G, 5%+) | 6,605,780 | 9.98% | 2026-03-31 |
| Vestal Point Capital, LP | Institution (13G, 5%+) | 5,425,000 | 8.20% | 2026-03-31 |
| Deep Track Capital, LP | Institution (13G, 5%+) | 4,062,500 | 6.14% | 2026-03-31 |
| BlackRock, Inc. | Institution (13G, 5%+) | 3,536,271 | 5.34% | 2026-06-30 |
Share count 66,172,934 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BCAX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →